康拓医疗(688314) - 2024 Q4 - 年度业绩

Financial Performance - In 2024, the company achieved total operating revenue of RMB 32,194.52 million, an increase of 17.06% compared to the previous year[6] - The net profit attributable to the parent company was RMB 8,857.08 million, reflecting a growth of 17.30% year-on-year[6] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 7,503.25 million, up by 9.77% from the previous year[6] - Earnings per share rose to RMB 1.09, an increase of 17.20% from RMB 0.93 in the previous year[4] - The weighted average return on net assets improved to 14.57%, an increase of 1.11 percentage points from the previous year[4] Assets and Equity - The company's total assets at the end of the reporting period were RMB 74,706.60 million, a growth of 10.55% from the beginning of the period[6] - The equity attributable to the parent company increased to RMB 63,575.27 million, representing an 8.27% increase compared to the beginning of the period[6] Revenue Growth - The revenue from PEEK material neurosurgical products reached RMB 20,595.87 million, marking a 23.00% increase year-on-year[6] - The company accelerated the admission of neurosurgical products and expanded coverage in lower-tier markets, contributing to the net profit growth[7] Audit and Reporting - The company emphasizes that the financial data is preliminary and subject to final audit in the annual report[8]